The AmpliSens consortium is led by BioEclosion S.L. CEO, Dr. Jofre Ferrer-Dalmau, and includes:
- Universitat Autònoma de Barcelona: Biosensing and Bioanalysis group.
P.I. Prof. María Isabel Pividori and Co-P.I. Prof. Mercè Martí - ISGlobal: P.I. Dr. Quique Bassat, MD. and Dra. Bàrbara Baro
- Eurecat: Functional Printing & Embedded Devices Group. P.I. Dra. Alejandra Ben Aissa
BioEclosion (coordinator Dr. Jofre Ferrer-Dalmau) partners with UAB-IBB team (PI: Prof. Isabel Pividori, expert in Rapid Diagnostic Tests), ISGlobal team (PI: Prof. Quique Bassat, key opinion leader in neonatal infections) and EureCat (for prototyping the product) in this acceleration phase, to build a reliable, scalable, and secure product faster and at the same time, ensuring compliance with the EU Regulation, for the rapid detection of GBS infection.
The combination of academic and industrial partners in the AmpliSens consortium, as well as clinical and basic science researchers working in research institutions, provides a highly complementary study team, which will deliver project aims according to chronogram. This, in combination with a valorization and commercialization plan, will pave the way for future large-scale implementation.
General data
AmpliSens– Enhancing Rapid Tests for perinatal GBS
Main goal – To develop a rapid and portable molecular test for the screen-out of neonatal sepsis due to GBS of the suspected newborn and for the screening of pregnant women
Funding programme – Project funded by the Ministry of Science and Innovation and by the European Union – Next Generation EU/PRTR, within the call ‘Proyectos de colaboración público-privada 2021’
Project reference – CPP2021-008459
Coordinator – BioEclosion S.L.
Duration – Sept 2022 – Aug 2025
